Published 27 June 2026 • By Dr. Megan Tranter
Beryllium is a lightweight, stiff, thermally stable metal indispensable to aerospace, defense, electronics, nuclear, and dental applications. It is also one of the most insidious occupational toxicants known, because the disease it causes is not a simple function of dose but an immune-mediated hypersensitivity that can be triggered by exposures far below those that injure other organs. A genetically susceptible worker may become sensitized to beryllium after only brief or low-level contact and may years later develop chronic beryllium disease (CBD), a granulomatous lung disorder clinically and histologically indistinguishable from sarcoidosis. This unusual immunological mechanism makes beryllium a paradigm of the limits of dose-based risk assessment and a continuing challenge for industrial-hygiene surveillance.
What You’ll Learn
- The industrial operations that generate hazardous beryllium exposure.
- How beryllium disease is driven by a beryllium-specific, cell-mediated immune response.
- The distinction between sensitization and chronic beryllium disease.
- The role of the beryllium lymphocyte proliferation test in surveillance.
- The OSHA permissible exposure limit, action level, and program requirements.
Introduction
Beryllium defies the conventional logic of dose-response toxicology. Because sensitization can follow minimal exposure in genetically susceptible individuals, the industrial hygienist cannot rely on a comfortable margin below a numerical limit. Instead, the goal is to minimize all exposure and to detect sensitization early through immunological surveillance. This article reviews the sources of exposure, the immunopathogenesis of beryllium disease, the progression from sensitization to clinical illness, the beryllium lymphocyte proliferation test, and the regulatory framework.
Sources and Industrial Uses
Occupational beryllium exposure occurs in the machining, grinding, and processing of beryllium metal, beryllium-copper and other alloys, and beryllium oxide ceramics. Workers in primary production, foundry and casting operations, metal recycling, dental laboratories, and abrasive blasting using beryllium-containing slags are at risk. The hazard is greatest where operations generate fine respirable particulate or fume. As with other hazardous metals discussed in our review of metal toxicity, particle size and solubility strongly influence deposition and biological availability, and the most hazardous exposures involve the respirable fraction that reaches the gas-exchange region of the lung.
Immunopathogenesis of Beryllium Disease
Beryllium disease is driven by a beryllium-specific, cell-mediated immune response. Inhaled beryllium acts as a hapten, binding to peptides presented by particular HLA-DP molecules and activating beryllium-specific CD4+ T lymphocytes. These T cells proliferate, secrete inflammatory cytokines, and orchestrate the formation of noncaseating granulomas in the lung. Because the principal route of harm is inhalation, though dermal contact can also induce sensitization, beryllium illustrates the importance of understanding the routes of entry by which a toxicant gains access to its target tissue. The genetic component means that susceptibility is unevenly distributed across the exposed population.
From Sensitization to Chronic Beryllium Disease
Beryllium sensitization is not itself a disease but an immunological state indicating that an individual has mounted a specific response to beryllium and is at risk of progressing to CBD. The rate of progression from sensitization to clinical disease is estimated at several percent per year, though it depends on the extent, timing, and physicochemical form of exposure as well as host genetics. CBD itself manifests as progressive dyspnea, cough, fatigue, and restrictive or mixed pulmonary impairment, and it may continue to develop years after exposure has ceased. The long latency and the indistinguishability from sarcoidosis make accurate diagnosis dependent on the demonstration of beryllium-specific immunity.
The Beryllium Lymphocyte Proliferation Test and Surveillance
The cornerstone of beryllium medical surveillance is the beryllium lymphocyte proliferation test (BeLPT), an in vitro assay that measures the proliferative response of a worker’s blood lymphocytes to beryllium salts. A confirmed abnormal result (typically two abnormal tests) establishes sensitization and prompts clinical evaluation, often including bronchoscopy with bronchoalveolar lavage and biopsy to confirm CBD. The BeLPT transformed beryllium surveillance by enabling the detection of at-risk workers before clinical disease appears. Because a single test has a non-trivial false-positive rate, confirmatory testing is standard practice, substantially improving specificity. The BeLPT exemplifies the broader logic of biological surveillance set out in our post on biological exposure indices.
The Regulatory Framework
OSHA’s beryllium standard, 29 CFR 1910.1024, sets a permissible exposure limit of 0.2 µg/m³ as an eight-hour time-weighted average and a short-term exposure limit of 2.0 µg/m³ over fifteen minutes, with an action level of 0.1 µg/m³. The standard requires exposure assessment, regulated areas, engineering and work-practice controls, respiratory protection, dermal protection, hygiene facilities, housekeeping, and medical surveillance, including periodic BeLPT testing. The International Agency for Research on Cancer classifies beryllium and beryllium compounds as Group 1 human carcinogens, adding lung cancer to the chronic granulomatous concern. Where exposures coexist with hexavalent chromium, the parallel controls described for hexavalent chromium apply.
Summary
Beryllium overturns dose-based intuition because sensitization can follow trace exposure in susceptible individuals. Pursue rigorous engineering controls to drive concentrations below the action level of 0.1 µg/m³, enforce dermal protection and housekeeping to prevent skin contact and take-home contamination, and enroll workers in BeLPT-based surveillance with confirmatory testing. Recognize that disease can emerge long after exposure ends, and treat beryllium with precaution commensurate with its capacity to cause irreversible illness.
Helpful Resources
- OSHA Beryllium Topic Page
- CDC NIOSH Beryllium Topic Page
- Related posts on this site: biological exposure indices and the toxicity of metals.
Bibliography
American Conference of Governmental Industrial Hygienists. (2026). TLVs and BEIs: Beryllium and compounds. ACGIH.
Balmes, J. R., Abraham, J. L., Dweik, R. A., Fireman, E., Fontenot, A. P., Maier, L. A., Muller-Quernheim, J., Ostiguy, G., Pepper, L. D., Saltini, C., Schuler, C. R., Takaro, T. K., & Wambach, P. F. (2014). An official American Thoracic Society statement: Diagnosis and management of beryllium sensitivity and chronic beryllium disease. American Journal of Respiratory and Critical Care Medicine, 190(10), e34-e59. https://doi.org/10.1164/rccm.201409-1722ST
Rose, V. E., & Cohrssen, B. (Eds.). (2011). Patty’s industrial hygiene (6th ed.). Wiley.
International Agency for Research on Cancer. (2012). Beryllium and beryllium compounds (IARC Monographs on the Evaluation of Carcinogenic Risks to Humans, Vol. 100C). IARC.
Mroz, M. M., Maier, L. A., Strand, M., Silviera, L., & Newman, L. S. (2009). Beryllium lymphocyte proliferation test surveillance identifies clinically significant beryllium disease. American Journal of Industrial Medicine, 52(10), 762-773. https://doi.org/10.1002/ajim.20736
National Institute for Occupational Safety and Health. (2007). NIOSH pocket guide to chemical hazards: Beryllium (DHHS NIOSH Publication No. 2005-149). NIOSH.
National Research Council. (2008). Managing health effects of beryllium exposure: Epidemiologic and clinical studies of beryllium sensitization and chronic beryllium disease. National Academies Press.
Occupational Safety and Health Administration. (n.d.). Beryllium (29 CFR 1910.1024). U.S. Department of Labor. https://www.osha.gov/laws-regs/regulations/standardnumber/1910/1910.1024
Plog, B. A., & Quinlan, P. J. (Eds.). (2012). Fundamentals of industrial hygiene (6th ed.). National Safety Council.
Jouanjan, L., Terschluse, C., Zissel, G., Agarwal, P., Wachenfeld, E., Quartucci, C., Soriano, D., Muller-Quernheim, J., Stolz, D., & Frye, B. C. (2025). Beryllium lymphocyte proliferation test: Differential diagnosis of sarcoidosis and chronic beryllium disease. Chest, 168(6), 1404-1414. https://doi.org/10.1016/j.chest.2025.06.034